Navigation Links
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
Date:6/29/2009

--Dr. Sherman also elected President of the Drug Information Association (DIA)--

NORTHBROOK, Ill., June 29 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P., as its executive vice president and chief medical officer.

Dr. Sherman brings more than 20 years of pharmaceutical experience to Horizon and will lead the regulatory and clinical strategy for Horizon's investigational therapies for mild-to-moderate arthritis and pain, including HZT-501, a fixed-dose combination tablet containing the most prescribed non-steroidal anti-inflammatory drug (NSAID), ibuprofen, with a high dose of the most potent H2 antagonist, famotidine. HZT-501 was shown to significantly reduce the incidence of NSAID-induced upper gastrointestinal ulcers in patients with mild-to-moderate pain in two Phase 3 studies.

Dr. Sherman joins Horizon from IDM Pharma, which was recently purchased by Takeda Pharmaceuticals Limited, where he led the clinical, regulatory, and development teams that secured European Commission approval for MEPACT(R) (mifamurtide, L-MTP-PE), a treatment for non-metastatic, resectable osteosarcoma. Prior to IDM Pharma, Dr. Sherman served as vice president of clinical science at Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he was focused on developing Takeda's oncology pipeline. Dr. Sherman also held the position of chief medical officer and executive vice president at NeoPharm, Inc., and held numerous research development and marketing roles at Searle/Pharmacia, including responsibility for the COX-2 (Celebrex) oncology program.

"Dr. Sherman has significant experience in the biotechnology and pharmaceutical industry, with a proven track record of success in bringing drugs through the regulatory process," said Timothy P. Walbert,
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use
2. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
3. Horizon Therapeutics Announces Senior Management Appointments
4. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
5. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
6. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
7. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
8. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
9. BioHorizons Announces the Purchase of Implant Logic Systems
10. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
11. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... to progressing its ground-breaking technology platforms to Phase 1 ... the Company delivers the best value for shareholders. ... said the Company currently had an extensive program of ... and academic partnerships and initiatives, and he was working ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for ... current system received a score of 0 (range -10 to +10) for its impact ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
...  Nabsys, Inc., a life sciences company pioneering development ... that data demonstrating the first direct electronic re-sequencing ... the annual Advances in Genome Biology and Technology ... Island, Fla., and the Omics and Personalized Medicine ...
... 13, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... 2012 Global Healthcare Conference on Wednesday, February 15, 2012.  ... The session may be accessed through the Company,s web ... page.  An archived version of the presentation will be ...
... Feb. 10, 2012  Neuland Laboratories Ltd., (NSE: NEULANDLAB; ... ingredients (APIs), complex intermediates and contract research and ... today announced financial results for the third quarter ... 2011. Revenues for the third ...
Cached Biology Technology:Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 2Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 3Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference 2Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results 2Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results 3
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... do it. Bees do it. Even environmentally stressed fish do ... of Zoology is the first in the world to discover ... His research may provide the key to the survival of ... ocean ― currently threatened by global warming. In ...
... than going it alone much longer than previously thought, according ... algae made the transition from being a single-celled organism to ... during the Triassic Period. At that time, Earth ... and early mammals. Previous estimates had suggested Volvox ,s ...
... When fruit flies mate, the females, genes are activated ... reaction starts. This is shown in a study at ... publication, Journal of Evolutionary Biology .* ... so-called microarrays, researchers at Uppsala University can show how ...
Cached Biology News:Changing sexes on the sea floor 2How Volvox got its groove 2How Volvox got its groove 3